May 21, 2025, 12:01 PM ETPanel

The Roadmap to Longevity | Global Conference 2025

Panelists: Dan Buettner (Blue Zones), Laura Deming (Longevity Fund/Cradle), Dr. Richard Isaacson (Atria Precision Prevention), Dr. Eric Verdin (Buck Institute), and Dr. Vonda Wright (Orthopedic Surgeon/Author).
Central Theme: The focus is shifting from merely extending "life span" to increasing "health span" (years of healthy life) and "brain span" (cognitive quality).
Lifestyle Determinism: Approximately 93% of health span and lifespan are determined by lifestyle factors rather than genetics, though genetics can influence individual susceptibility.
The "One Hack" Consensus: Panelists largely rejected the concept of a single life-extending "hack," emphasizing instead that longevity requires a multi-faceted approach involving nutrition, sleep, physical activity, stress mitigation, and social connection.

Dan Buettner (Blue Zones & Population Health)

Dietary Data: A meta-analysis of 155 studies across five Blue Zones reveals centenarians consume a 90% whole-food, plant-based diet, eating only ~20 lbs of meat annually (vs. 220 lbs for the average American).
Specific Food Impact: Consuming one cup of beans daily correlates with approximately four extra years of life expectancy.
Social Factor: In Sardinia, having five or more daughters is the third strongest predictor of a man living to 100, though the causal mechanism (caregiving vs. genetic resilience) remains unclear.
Behavioral Environment: Health is best sustained when unconscious behaviors are governed by environment rather than conscious will; people do not "try" to be healthy in Blue Zones.
Urban Design: Walkable cities (e.g., Boulder, NYC) provide ~10,000 daily steps automatically, whereas sprawling cities (e.g., Phoenix, Houston) provide ~4,000; this 6,000-step difference reduces all-cause mortality by ~45%, equating to 4–5 years of life expectancy.
Happiness Curve: Happiness follows a U-shaped curve, dipping in the 45–55 age range but rising for those over 100, with centenarians being the happiest demographic.

Laura Deming (Longevity Science & Venture Capital)

Drug Approval: The first FDA-approved drug for lifespan extension is expected within the next year, likely for dogs (company: Loyal), marking a historic precedent for labeling drugs as "longevity" therapeutics.
Cryopreservation: Deming identifies medical hibernation (cryopreservation) as a potential "bridge" for terminal patients, allowing them to pause biological time until future cures (e.g., for dementia or cancer) become available.
Current Reality Check: No intervention currently extends human life by decades; claims of 50+ years of extension are "bullshit," though deterministic increases are scientifically feasible.
Funding Models: A rise in "Focused Research Organizations" (FROs) is emerging to tackle ambitious, multi-disciplinary projects ($15M–$100M funding) that are too large for single labs but not yet large enough for traditional biotech scale-ups.

Dr. Richard Isaacson (Alzheimer's Prevention)

Prevention Potential: Conservative estimates suggest 45% of dementia cases are preventable through comprehensive lifestyle and precision medicine interventions.
Intervention Impact: A comprehensive 18-month precision medicine program can delay the onset of Alzheimer's symptoms by 4 to 8 years.
Precision Medicine: Treatment plans must be gender-specific; women's critical window for brain health is perimenopause, where hormone replacement therapy can mitigate risk for the 25% of women with high-risk genes.
Emerging Diagnostics: Blood-based biomarkers for Alzheimer's are in development, moving from "black and white" to "color/high-def" predictive testing similar to current cholesterol panels.
Drug Synergy: GLP-1 agonists (e.g., Ozempic, Zepbound) show promise for brain health when deployed via precision medicine, though they are not a standalone cure.

Dr. Eric Verdin (Biomedical Aging Research)

Aging as a Variable: Aging is a malleable parameter; in animal models, single genetic mutations can double life expectancy (worms) or increase it 10-fold, while mice see ~1.5x increases.
Existing Drugs: Several existing drugs (Metformin, Rapamycin, GLP-1s) behave as anti-aging interventions in animal models, though no supplement or drug is yet documented to safely extend human lifespan.
Lifestyle Efficacy: Optimizing all known lifestyle factors (nutrition, sleep, exercise, etc.) can yield 15–20 years of additional healthy life, pushing average healthy life expectancy to 90–95 years.
Public Sector Warning: The NIH is the primary driver of biomedical innovation (98% of FDA-approved drugs in the last 5 years originated from NIH grants); budget cuts threaten to destroy the "mother goose" of discovery and cause a "brain drain" of young scientists to Europe (which recently offered $100B to recruit US talent).
Future Outlook: The 21st century is poised to be the "century of biology," with the next 50–100 years expected to yield transformative medical advances comparable to the physics revolution of the 20th century.

Dr. Vonda Wright (Orthopedics & Women's Health)

Grip Strength: Grip strength is a primary predictor of life expectancy; Wright maintains a daily hour of physical activity, viewing exercise as essential "religion" for health.
Bone Health: Peak bone mass is reached at age 30; "bashing bones" (impact activities like jumping/running) is critical for building resilience, especially for children and adolescents.
Gender Differences: Men and women age biologically differently at the cellular level; women face a "cataclysmic" hormonal shift (menopause) that accelerates tissue decline, unlike the gradual testosterone decline in men.
Research Gap: Women's health research receives only 1% of all health research funding and 2% of venture capital, despite women representing the majority of the population.

Healthcare Reform: The current system is criticized as "sick care" rather than "health care," focusing on salvaging health after 65–70 rather than prevention; a shift to proactive prevention is necessary.
Funding Crisis: Scientists express significant fear regarding the next 3–4 years, citing slashed federal budgets, failed grant applications, and a lack of viable alternatives to NIH funding for large-scale research.
Democratization: A key goal for the field is ensuring longevity medicine becomes accessible to all, not just the wealthy, as it currently risks becoming a luxury service.
Global Disparity: Americans lag behind populations in Scandinavia, Southeast Asia, and the Mediterranean, who enjoy 12 extra years of healthy life due to societal nudges and policies.
Key Policy Driver: Educating women of childbearing age is identified as the single most powerful policy intervention to raise national life expectancy, creating an intergenerational spiral of health and productivity.
Timeline for Approval: Dr. Verdin predicts at least one FDA-approved drug targeting the aging process will be available within the next five years, citing at least five Phase III clinical trials currently underway.